Myolimus

Drug Profile

Myolimus

Alternative Names: Myolimus-eluting stent

Latest Information Update: 28 Mar 2014

Price : $50

At a glance

  • Originator Novartis
  • Developer Elixir Medical Corporation
  • Class Cardiovascular therapies; Lactones; Macrolides
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Coronary artery restenosis

Most Recent Events

  • 17 May 2012 Elixir Medical Corporation completes the DESolve-I phase I trial in Coronary artery restenosis (prevention) in Belgium and New Zealand (NCT02086006)
  • 16 May 2012 Interim adverse events data from a phase I trial in Coronary artery restenosis (prevention) released by Elixir Medical
  • 29 Oct 2008 Phase-I clinical trials in Coronary artery restenosis (prevention) in New Zealand (Intra-arterial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top